Alnylam Pharmaceuticals Inc (ALNY) Profitability Comparisons, Net Margin, Gross Margin, Tax rate, Cash Flow Margin Comparisons - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Alnylam Pharmaceuticals Inc   (NASDAQ: ALNY)

Alnylam Pharmaceuticals Inc Profitability Comparisons

Select each Category to receive further Information



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ALNY Profitability Ratio

 Company Industry Sector S&P 500
Gross Profit Margin (Q1 MRQ) 82.22 % 70.91 % 65.43 % 46.06 %
Gross Margin (Q1 TTM) 81 % 71.73 % 66.39 % 46.3 %
Gross Profit Margin 5 Yr. Avg. 85.27 % 66.05 % 64.67 % 47.07 %
EBITDA Margin (Q1 MRQ) 20.15 % 22.25 % 19.59 % 20.57 %
EBITDA Margin (Q1 TTM) 15.95 % 25.28 % 20.86 % 19.07 %
EBITDA Margin 5 Yr. Avg. --36.94 % 45.98 % 31.16 % 22.06 %
Operating Margin (Q1 MRQ) 23.02 % 17.27 % 16.57 % 16.03 %
Operating Margin (Q1 TTM) 17.54 % 20.33 % 17.92 % 16.33 %
Operating Margin 5 Yr. Avg. --33.88 % 15.55 % 14.41 % 17.09 %
Pre-Tax Profit Margin (Q1 MRQ) 18.99 % 13.66 % 10.93 % 13.94 %
Pre-Tax Profit Margin (Q1 TTM) 13.68 % 16.7 % 12.86 % 13.09 %
Pre-Tax Profit Margin 5 Yr. Avg. - 13.09 % 10.45 % 12.49 %
Net Margin (Q1 MRQ) 17.65 % 10.09 % 8.14 % 11.41 %
Net Margin (Q1 TTM) 13.46 % 13.13 % 9.99 % 10.76 %
Net Margin 5 Yr. Avg. - 6.22 % 6.23 % 9.95 %



Business Segment Profit Margin
 
Net product revenues
  Explore Net product revenues Segment  -
Total TTR
  Explore Total TTR Segment  -
AMVUTTRA
  Explore AMVUTTRA Segment  -
ONPATTRO
  Explore ONPATTRO Segment  -
Total Rare
  Explore Total Rare Segment  -
GIVLAARI
  Explore GIVLAARI Segment  -
OXLUMO
  Explore OXLUMO Segment  -
United States AMVUTTRA
  Explore United States AMVUTTRA Segment  -
United States ONPATTRO
  Explore United States ONPATTRO Segment  -
United States GIVLAARI
  Explore United States GIVLAARI Segment  -
United States OXLUMO
  Explore United States OXLUMO Segment  -
Europe AMVUTTRA
  Explore Europe AMVUTTRA Segment  -
Europe ONPATTRO
  Explore Europe ONPATTRO Segment  -
Europe GIVLAARI
  Explore Europe GIVLAARI Segment  -
Europe OXLUMO
  Explore Europe OXLUMO Segment  -
Rest of World AMVUTTRA
  Explore Rest of World AMVUTTRA Segment  -
Rest of World ONPATTRO
  Explore Rest of World ONPATTRO Segment  -
Rest of World GIVLAARI
  Explore Rest of World GIVLAARI Segment  -
Rest of World OXLUMO
  Explore Rest of World OXLUMO Segment  -
Net revenues from collaborations
  Explore Net revenues from collaborations Segment  -
Net revenues from collaborations Roche
  Explore Net revenues from collaborations Roche Segment  -
Net revenues from collaborations Regeneron Pharmaceuticals
  Explore Net revenues from collaborations Regeneron Pharmaceuticals Segment  -
Net revenues from collaborations Other
  Explore Net revenues from collaborations Other Segment  -
Regeneron Pharmaceuticals Research Services Obligation Global Strategic Collaboration
  Explore Regeneron Pharmaceuticals Research Services Obligation Global Strategic Collaboration Segment  -
Regeneron Pharmaceuticals
  Explore Regeneron Pharmaceuticals Segment  -
Global Strategic Collaboration Regeneron Pharmaceuticals Research Services Obligation
  Explore Global Strategic Collaboration Regeneron Pharmaceuticals Research Services Obligation Segment  -
Global Strategic Collaboration Regeneron Pharmaceuticals Other license programs
  Explore Global Strategic Collaboration Regeneron Pharmaceuticals Other license programs Segment  -
Roche Roche Collaboration and License Agreement
  Explore Roche Roche Collaboration and License Agreement Segment  -
Roche Roche Development Services Obligation Roche Collaboration and License Agreement
  Explore Roche Roche Development Services Obligation Roche Collaboration and License Agreement Segment  -
Roche Other Roche Collaboration and License Agreement
  Explore Roche Other Roche Collaboration and License Agreement Segment  -
Regeneron Pharmaceuticals Other license programs Global Strategic Collaboration
  Explore Regeneron Pharmaceuticals Other license programs Global Strategic Collaboration Segment  -
 

Company's Cashflow Profitability & Other



Profitability Ratios Company Industry Sector S&P 500
Free Cash Flow Margin (Q1 MRQ) 4.17 % -0.01 % 0.21 % 1.39 %
Free Cash Flow Margin (Q1 TTM) 14.96 % 17.24 % 13.98 % 9.19 %
Free Cash Flow Margin 5 Yr. Avg. - 20.2 % 15.38 % 14.52 %
Net Cash Flow Margin (Q1 MRQ) 4.59 % 0.02 % -0.02 % 0.13 %
Net Cash Flow Margin (Q1 TTM) 16.1 % -0.78 % 0.08 % 1.81 %
Net Cash Flow Margin 5 Yr. Avg. - 4.28 % 3.13 % 5.85 %
Effective Tax Rate (Q1 MRQ) 7.07 % 25.98 % 25.41 % 18.83 %
Effective Tax Rate (Q1 TTM) 1.57 % 21.22 % 22.81 % 19.33 %
Effective Tax Rate 5 Yr. Avg. - 15.14 % 20.39 % 19.86 %
Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.